about us   |   contact us   |   links   |   sitemap

Brain-Supplements.com 

home   |   forum   |    studies   |   brain games
brain supplements piracetam aniracetam oxiracetam centrophenoxine Meclofenoxate brain formulas vitamins

5-HTP  |  Acetyl L-Carnitine  |  Alpha GPC  |  Alpha Lipoic Acid  |  Aniracetam  |  Ashwagandha  |  Centrophenoxine

 CoEnzyme Q-10  |  DHA  |  DMAE  |  GABA  |  Huperzine A  |  Idebenone  |  Inositol  |  L-Dopa  |  Lecithin  |  Mucuna Pruriens   

Oxiracetam  |  Phenylalanine
  |  Phosphatidyl Serine  |  Phenylethylamine Picamilon  |  Piracetam  |  Pyritinol  |  Sulbutiamine

Rhodiola Rosea  |  Theanine  |  Tryptophan  |  Vitamin B-6  |  Vitamin C  |  Tyrosine
 





Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.

Chan PL, Nutt JG, Holford NH

Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.
 

PURPOSE: To externally validate the model predictions of a DATATOP cohort analysis through application of clinical trial simulation with the study design of the ELLDOPA trial. METHODS: The stochastic pharmacokinetic-pharmacodynamic and disease progress model was developed from the large DATATOP cohort of patients followed for 8 years. ELLDOPA was designed to detect a difference between placebo and levodopa treated arms in the total Unified Parkinson's Disease Rating Scale (UPDRS) taken at baseline and following 2 weeks levodopa washout after 40 weeks of treatment. The total UPDRS response was simulated with different assumptions on levodopa effect (symptomatic with/without disease modifying capability) and washout speed of symptomatic effect.

RESULTS: The observed results of ELLDOPA were similar to the model predictions assuming levodopa slows disease progression and has a slow washout of symptomatic effect. CONCLUSIONS: This simulation work confirmed the conclusion of the DATATOP analysis finding that levodopa slows disease progression. The simulation results also showed that a dose-related increased rate of progression in Parkinson's disease, obscured by symptomatic benefit, is very unlikely. Finally, the simulation results also shown that 2 weeks washout period was not adequate to completely eliminate the symptomatic benefits of levodopa.

L-Dopa         _____________            ________

Unique Nutrition L-DOPA 250 mg 120 caps






Retail: $52.99
Our Price:
$28.45

 
 
Mucuna Pruriens     _____________________

Nutraceutics Rx Mucuna Pruriens 250mg 120 Caps standardized to 40% L-Dopa




Retail: $49.95
Our Price:
$19.95

Nutraceutics Rx Mucuna Pruriens 625mg 120 Caps





Retail:
$59.95
Our Price:
$39.95